Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBT (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed EBT for 15 consecutive years, with -$99.2 million as the latest value for Q1 2026.

  • For Q1 2026, EBT fell 9.6% year-over-year to -$99.2 million; the TTM value through Mar 2026 reached -$424.3 million, down 159.97%, while the annual FY2025 figure was -$413.8 million, 157.63% down from the prior year.
  • EBT hit -$99.2 million in Q1 2026 for Agios Pharmaceuticals, up from -$109.1 million in the prior quarter.
  • Across five years, EBT topped out at $1.0 billion in Q3 2024 and bottomed at -$112.5 million in Q2 2025.
  • Average EBT over 5 years is -$31.3 million, with a median of -$95.8 million recorded in 2022.
  • Year-over-year, EBT soared 1196.14% in 2024 and then plummeted 110.33% in 2025.
  • Agios Pharmaceuticals' EBT stood at -$92.7 million in 2022, then fell by 3.51% to -$95.9 million in 2023, then decreased by 9.86% to -$105.4 million in 2024, then decreased by 3.47% to -$109.1 million in 2025, then grew by 9.01% to -$99.2 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$99.2 million, -$109.1 million, and -$103.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.